Hepatitis C Therapeutics in Major Developed Markets to 2019 Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape Publisher: GBI Research No of pages: 120 Publish Date: Jan2014
Description GBI Research, has released the pharma report, “Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape”. The current Hepatitis C treatment landscape consists of a combination of pegylated interferon, ribavirin and, in patients infected with genotype 1 hepatitis C, one of two direct-acting antiviral agents (DAAs). Products with these mechanisms of action have performed strongly in the commercial setting, with the market leader Incivek (a DAA) having reached blockbuster sales. However, these products are very poorly tolerated and only moderately efficacious. The approval of the DAA Sovaldi in December 2013 changed this, with a complete viral clearance being achieved in close to 100% of patients and a much improved adverse event profile compared to previous standards of therapy. In patients with genotype 2 and 3 hepatitis C, Sovaldi does not need to be administered with pegylated interferon.
Description A number of products in the late-stage pipeline, which promise to be even more efficacious and safe are anticipated to enter the market over the forecast period, including several interferon-free therapies for genotype 1-infected patients. As a result of this, as well as an overall increase in the treated population, GBI Research believes the global market has the potential to grow to a value of $18.6 billion by 2019, more than tripling the 2012 market value of $5.8 billion. Enquire about report at: http://www.reportsandintelligence.com/enquire-about-report/132419
Scope • A brief introduction to hepatitis C, including the disease’s pathogenesis, risk factors and diagnosis, and detailed analyses of disease epidemiology and treatment algorithms. • In-depth analysis of the major antiviral drugs used in the treatment of hepatitis C, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map that compares marketed drugs in terms of safety and efficacy. • A comprehensive review of the pipeline for hepatitis C therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed by phase distribution, molecule type and molecular target. • In-depth clinical trial enrolment, trial duration and program failure rate analyses for each molecule type and mechanism of action. Additionally, clinical trial endpoints and certain selection criteria are analyzed in great depth. This section also includes an additional heat map regarding pipeline products, and a direct cross-analysis against currently marketed products.
Reasons to buy • Understand the different types of hepatitis C therapies and how treatment varies by genotype. • Understand the treatment algorithms and guidelines related to hepatitis C, how they are anticipated to change during the forecast period and where opportunities and unmet needs lie. • Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are most prominent. • Observe trends in clinical trial duration and size as clinical phase and molecule type varies. Use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for hepatitis C therapeutics. • Observe the shift in clinical trial endpoints with each clinical Phase, and use this data to potentially influence any future developmental programs. Additionally, understand the trends in enrolment by patient genotype. • Assess the potential clinical and commercial impact of current late-stage pipeline molecules and the points of opportunity which remain to be capitalized upon.
Table Of Content 1 Table of Contents1 Table of Contents 51.1 List of Tables 81.2 List of Figures 92 Introduction 102.1 Signs and Symptoms 102.2 Etiology and Risk Factors 112.3 Pathophysiology 112.4 Epidemiology 122.4.1 US and Canada 122.4.2 Europe 122.4.3 Japan 132.4.4 Regional Prevalence of Hepatitis C Genotypes 132.5 Prognosis 142.6 Diagnosis and Screening 16 2.7 Treatment 162.8 Treatment Algorithms 17
Table Of Content 3 Marketed Products 213.1 Ribavirin 213.2 Pegasys (Peginterferonalfa 2a) and PegIntron (Peginterferonalfa 2b) - Hoffmann La Roche and Merck & Co 223.2.1 Pegasys - Hoffmann La Roche 243.2.2 PegIntron - Merck & Co 243.3 Incivek (telaprevir) - Vertex Pharmaceuticals and Janssen-Cilag 253.4 Victrelis (boceprevir) - Merck & Co 263.5 Olysio (simeprevir) - Johnson and Johnson 273.6 Sovaldi (sofosbuvir) - Gilead Sciences 283.7 Heat Map for Marketed Products 294 Developmental Pipeline 314.1 Overall Pipeline 314.2 Mechanisms of Action 33 4.3 Clinical Trials 354.3.1 Clinical Trial Failure Rates 364.3.2 Clinical Trial Enrollment 37
Table Of Content 4.3.3 Clinical Trial Duration 394.3.4 Clinical Trial Design 414.4 Promising Pipeline Drugs 444.4.1 Sovaldi plus Ledipasvir - Gilead Sciences 444.4.2 Daclatasvir - Bristol-Myers Squibb 464.4.3 Faldaprevir - Boehringer-Ingelheim 494.4.4 Peginterferon lambda 1a - Bristol-Myers Squibb 504.4.5 ABT-450 - AbbVie and Enanta 524.4.6 Vaniprevir - Merck & Co 54 4.5 Heat Map and Competitor Matrix for Pipeline Products 554.6 Conclusion 595 Market Forecast to 2019 61 Get full TOC at: http://www.reportsandintelligence.com/hepatitis-c-therapeutics-in-major-developed-to-2019-outstanding-recent-approvals-and-late-stage-pipeline-to-transform-clinical-and-commercial-landscape-market/table-of-contents
FOR MORE DETAILS Visit us at : http://www.reportsandintelligence.com/hepatitis-c-therapeutics-in-major-developed-to-2019-outstanding-recent-approvals-and-late-stage-pipeline-to-transform-clinical-and-commercial-landscape-market Stay With Us: • TELEPHONE: Direct: +1 (617) 674-4143 • Toll Free: +1 (855) 711-1555E-MAIL: email@example.com 5933 NE Win Sivers Drive,#205, Portland, OR 97220United States